Rezubio Pharmaceuticals advanced RZ-520 for chronic respiratory diseases into Phase I after IND clearances from both the FDA and China’s NMPA, with dosing underway in healthy volunteers. In parallel, Acepodia obtained FDA IND clearance for ACE-723, a GPC3-targeted dual-payload antibody-drug conjugate planned for Phase I in unresectable or metastatic hepatocellular carcinoma. Together, the actions show continued cross-regulatory momentum for first-in-human programs—particularly in respiratory disease and liver cancer where targeted biologics and immune-oncology strategies are intensifying. For investors and competitors, the simultaneous start of Phase I dosing provides near-term readouts on safety and pharmacology. Both companies will now prioritize cohort expansion and biomarker strategy to demonstrate clinical tractability, especially for ADCs where early exposure–response signals can influence subsequent dose and combination plans.